Skip to content

Survey on Fear of Relapse/Progression and Attitudes Towards AI Psychological Support Tools Among Multiple Myeloma Patients and Family Members of Multiple Myeloma Patients

Survey on Fear of Relapse/Progression and Attitudes Towards AI Psychological Support Tools Among Multiple Myeloma Patients and Family Members of Multiple Myeloma Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126377
Enrollment
Unknown
Registered
2026-06-08
Start date
2025-10-02
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma (MM)

Interventions

Clinically Significant Fear of Cancer Recurrence group:None
non-Clinically Significant Fear of Cancer Recurrence group:None

Sponsors

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients (age >= 18 years) with a confirmed diagnosis of multiple myeloma; 2. Patients who were in remission or had recovered after treatment; 3. Ability to read Chinese and complete the questionnaire.

Exclusion criteria

Exclusion criteria: 1.Except the patients who are inconformity with the inclusion criteria;

Design outcomes

Primary

MeasureTime frame
Prevalence of clinically significant fear of cancer recurrence in patients with multiple myeloma;

Secondary

MeasureTime frame
Acceptance and preferences regarding artificial intelligence-assisted psychological support tools;Baseline demographic, clinical, and caregiving-related characteristics;Health-related quality of life;

Countries

China

Contacts

Public ContactChunrui Li

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

cunrui5650@hust.edu.cn+86 27 8366 5047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026